Adrian Gottschalk compensation by year
Foghorn Therapeutics Summary Compensation Table · all 7 fiscal years held| Component | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Salary | $465,000 | $478,950 | $540,000 | $575,000 | $579,000 | $601,500 | $638,000 |
| Bonus | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Stock awards | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Option awards | $642,918 | $1,834,007 | $3,370,482 | $4,645,819 | $1,719,292 | $673,861 | $1,334,037 |
| Non-equity incentive | $197,625 | $311,318 | $405,000 | $215,625 | $202,650 | $281,201 | $385,990 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| All other | $0 | $0 | $0 | $0 | $3,000 | $3,000 | $3,000 |
| Total | $1,305,543 | $2,624,275 | $4,315,482 | $5,436,444 | $2,503,942 | $1,559,562 | $2,361,027 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Foghorn Therapeutics Inc. DEF 14A filed April 30, 2026, accession 0001193125-26-193928, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Foghorn Therapeutics Inc. filed document, accession 0001193125-26-193928. Every figure is read from that document and cited to the page and table it appears in. Filed April 30, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| Option | 27,500 | — | $14.87 |
| Option | 87,500 | — | $8.38 |
| Option | 168,750 | — | $3.06 |
| Option | 400,000 | — | $4.37 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Foghorn Therapeutics Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Foghorn Therapeutics’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Adrian Gottschalk · this page | President and Chief Executive Officer | $2,361,027 |
| Steven Bellon | Chief Scientific Officer | $1,199,455 |
| Alfonso Quintas-Cardama | Chief Medical Officer | $1,133,965 |
Board service
Foghorn Therapeutics board · FY2021–FY2025How this board is paid
Company policy: Foghorn Therapeutics pays directors a $40,000 cash retainer. As stated in Foghorn Therapeutics's FY2025 proxy.
The full Foghorn Therapeutics compensation record
free company briefThis page is one person within Foghorn Therapeutics's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Foghorn Therapeutics's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Foghorn Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Order FHTX
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.